CD10 expression in the neuroendocrine carcinoma component of endometrial mixed carcinoma: association with long survival

Karina Uehara1, Fukino Ikehara1, Yasuka Tanabe1, Iwao Nakazato2, Mariko Oshiro3, Morihiko Inamine4 and Takao Kinjo1*

Abstract

Background: Endometrial mixed carcinoma with the neuroendocrine carcinoma (NEC) component is rare and is believed to have a poor prognosis. CD10 expression is reported to be a favorable prognostic marker for some tumors such as B-lymphoblastic leukemia/lymphoma, but unfavorable for others. Here, we report the case of a 33-year-old woman diagnosed with endometrial mixed carcinoma with the NEC component expressing CD10 who showed a favorable outcome.

Case presentation: The patient presented with lumbago and brownish discharge from the genitals. Imaging modalities revealed a large exophytic mass in the uterine corpus, and a small one in the uterine cervix. Radical hysterectomy with bilateral salpingo-oophorectomy was performed. Microscopic examination of the endometrial and cervical masses revealed that the NEC component accounted for the maximum area in both masses. However, small areas in both lesions showed well differentiated endometrioid adenocarcinoma (WDEA) components, and histological transition between the two components was also observed. In addition to CD56 and synaptophysin expression, the NEC component was positive for CD10 but negative for estrogen receptor (ER), progesterone receptor (PgR), and carcinoembryonic antigen (CEA). In contrast, the WDEA component expressed both ER and PgR, but neither CD10 nor neuroendocrine markers were demonstrated. The CD10 and neuroendocrine markers clearly distinguished between the NEC and WDEA components. Furthermore, retained expression of phosphatase and tensin homolog (PTEN) and weak phosphorylated Akt expression were found, which were assumed to suppress the aggressive behavior of the tumor. The patient received postoperative chemotherapy and has survived without recurrence for 6 years after the operation.

Conclusion: This is the first case of endometrial mixed carcinoma with the NEC component expressing CD10 that showed a long survival.

Keywords: Endometrial mixed carcinoma, Neuroendocrine carcinoma, Well differentiated endometrioid adenocarcinoma, CD10, PTEN, Long survival

* Correspondence: kinjotko@med.u-ryukyu.ac.jp

1Division of Morphological Pathology, Department of Basic Laboratory Sciences, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan
Full list of author information is available at the end of the article

© 2016 Uehara et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Endometrial mixed carcinoma has recently been defined as a new entity of gynecological carcinoma. It is defined as a tumor composed of two or more histological types of endometrial carcinoma, at least one of which is of the type II category [1]. Most common mixed carcinomas consist of endometrioid and serous carcinoma components, however, the prevalence of mixed carcinoma with the neuroendocrine carcinoma (NEC) component is very rare [1, 2]. Among mixed carcinomas with the NEC component, the most common combination is with endometrioid adenocarcinoma (EA) [3, 4]. The prognosis of mixed carcinoma correlates with the highest-grade component [1]. Because the prognosis for endometrial small cell NEC and large cell NEC is poor [3, 4], it is considered that the prognosis of mixed carcinoma with the NEC component is unfavorable. Huntsman et al. reported the clinicopathological findings of 16 cases of small cell NEC, including 10 patients of mixed carcinoma with small cell NEC component. Among these 10 cases, 6 patients died between 2 months and 4 years postoperatively, 1 survived but exhibited multiple metastases [2]. Furthermore, Mulvany and Allen reported 5 cases of large cell NEC including 4 patients of mixed carcinoma with large cell NEC component showing that half of the mix carcinoma patients died within 2 years [5]. With regard to the association between clinical stage and prognosis of mixed carcinoma with small cell NEC component, Katahira et al. reviewed the literature and found that only 23 % of patients with International Federation of Gynecology and Obstetrics (FIGO) stage I died within 5 years, whereas 73 % of patients with stage II-IV died within 2 years [6]. Although the prognosis of endometrial mixed carcinoma with the NEC component is regarded as poor, especially advanced FIGO stage, very small number of long survival cases was reported [2, 7–9]. Half of the long surviving cases were early FIGO stage, however, the other factor(s) that may influence or correlate with favorable prognosis remain unclear.

CD10 is a cell-surface neutral endopeptidase and is distributed ubiquitously in various tissues. It is associated with multiple biological functions such as cellular proliferation, migration, differentiation and stem cell maintenance [10]. CD10 is expressed in several malignancies and through these functions CD10 is associated with biological properties of cancer including invasion, metastasis, and sensitivity to chemotherapy [10]. CD10 expression is a good prognostic marker in B-lymphoblastic leukemia/lymphoma [11], uterine cervical cancer [12], and non-small cell lung cancer [13]. On the other hand, it is a poor prognostic marker in several cancers such as gastric, pancreatic, colorectal carcinomas [14], melanoma [15], and skin cancers [16]. The significance of CD10 expression in endometrial mixed carcinoma with the NEC component is currently unknown.

Here we report a case of endometrial mixed carcinoma with the NEC component expressing CD10 at FIGO stage II. By immunohistochemistry, retained expression of phosphatase and tensin homolog (PTEN) and weak phosphorylated Akt expression were found in the NEC component, which may contribute to suppress the aggressive behavior of the tumor. The patient is alive without tumor recurrence for 6 years after surgery. To the best of our knowledge, this is the first case indicating the association between CD10 expression and favorable outcomes of mixed carcinoma with the NEC component.

Case presentation
A 33-year-old woman presented with lumbago and brownish discharge from the genitals, which persisted for 3 months and continued to worsen. Physical examination and imaging modalities revealed exophytic tumors located in the uterine cervix and uterine corpus. As endometrioid carcinoma with neuroendocrine differentiation was suspected on the basis of preoperative biopsy, radical hysterectomy with bilateral salpingo-oophorectomy was performed. The patient received postoperative chemotherapy and has exhibited no recurrence for 6 years postoperatively.

Table 1 Primary antibodies used in this study

| Marker            | Source      | Dilution | Clone/code |
|-------------------|-------------|----------|------------|
| AE1/AE3           | Dako        | x800     | M3515      |
| 34β-E12           | Dako        | x200     | M0630      |
| CAM 5.2           | Ventana     | diluted  | CAM 5.2    |
| EMA               | Dako        | x100     | E29        |
| CEA               | Dako        | x150     | II-7       |
| ER                | Ventana     | diluted  | SP1        |
| PgR               | Ventana     | diluted  | 1E2        |
| CD10              | Dako        | x80      | 552/36     |
| CD56              | Novocastra  | x100     | B6         |
| Chromogranin      | Dako        | x100     | DAK-A3     |
| Synaptophysin     | Dako        | x400     | A0010      |
| S-100             | Dako        | x2000    | ER-PR8     |
| p16               | Abcam       | x200     | 2D9A12     |
| AKT1              | Abcam       | x100     | ab54753    |
| AKT1 (phospho S473) | Abcam    | x100     | 104A282    |
| PTEN              | Abcam       | x150     | EPR9941    |
| β-catenin         | Millipore   | x500     | E247       |
Methods
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed and paraffin embedded tissues. Four-micron sections were pretreated in citrate buffer (pH 6.0) in a microwave oven for antigen retrieval. The primary antibodies used in this study are shown in Table 1. The primary antibody reaction was performed at room temperature for 60 min, and the signal was detected using the LSAB 2 HRP system (DAKO) with liquid diaminobenzidine as the substrate chromogen.

Results
Gross findings
The uterus along with both ovaries and fallopian tubes weighed 225 g. On sectioning, large bulky tumors were found in the uterine endometrium and uterine cervix (Fig. 1). The endometrial tumor measured 40 × 40 mm and showed deep invasion into the muscle layer. However, the serosal surface was not involved. The cervical tumor measured 28 × 28 mm and infiltrated into the uterine cervical stroma, but did not extend beyond the uterus. Based on these findings, the patient’s postsurgical stage was defined as FIGO stage II.

Microscopic findings
Most of the bulky and ill-defined masses from the endometrium and cervix consisted of broad trabecular, solid sheets and irregular gland-like structures of cancer cells with vesicular nuclei, prominent nucleoli, and faintly eosinophilic cytoplasm. Peripheral palisading and central necrosis were apparent (Fig. 2a). These findings suggested NEC. Mitotic figures were conspicuous at 5–12 per 10 high-power fields (HPF). The NEC cells of the endometrial tumor invaded the myometrium to more

---

**Fig. 1** Macroscopic characteristics of the tumors. Bulky and solid tumors with whitish color are observed in the fundus (※※) and cervix (※). Large tumor (※※) arising from the endometrial mucosa of the fundus and invading the deep muscle layer. Small tumor (※) limited to the cervical mucosa, with no muscle layer invasion.

**Fig. 2** Microscopic findings of the tumors. a: The NEC component shows solid sheets and irregular gland-like structures with vesicular nuclei and prominent nucleoli. Necrosis and rosette formation are noted. b: The WDEA component shows irregular tubular structures with cribriform pattern and complex folds. c: Histological transition is observed at the boundary between the NEC and WDEA components. Original magnification: a, b: ×200, c: ×100
than half its depth. The NEC cells of the cervical tumor infiltrated the cervical stroma, but did not reach the muscle layer. Lymphovascular invasion was observed, but no lymph node metastasis was identified. In small areas of the endometrial and cervical tumors, the cancer cells showed an atypical columnar shape with enlarged nuclei located on the basal side, irregular tubular glands showing a back-to-back structure, and complex fold formation.

Fig. 3 Immunohistochemical profile of the present case. a. The NEC component shows marked CD10 expression, whereas WDEA does not. b. CD56 immunoreactivity is observed in the NEC component. c. ER expression is not detected in the NEC component, but strong ER expression is demonstrated in the WDEA component. d. Neither the NEC component nor the WDEA component exhibits CEA expression. e. p16 is not noted in the WDEA component. f. PTEN expression is weak but diffusely detected in the NEC component. g. Phosphorylated AKT is detected faintly in the NEC component.
Solid nests of cancer cells occupied less than 5% of both lesions (Fig. 2b). These findings corresponded with well differentiated endometrioid adenocarcinoma (WDEA). Histological transition was observed at the boundary between the NEC and WDEA components (Fig. 2c). Immunohistochemistry revealed that the NEC components in both endometrial and cervical tumors were strongly immunoreactive for CD10, positive for CD56, weakly positive for synaptophysin and p16, and negative for estrogen receptor (ER), progesterone receptor (PgR), carcinoembryonic antigen (CEA), and chromogranin (Fig. 3a-e). The NEC component was also positive for PTEN, comparable to the nuclear expression of stromal cells, whereas phosphorylated Akt was observed weakly in the cytoplasm (Fig. 3f, g). The WDEA components of both tumors were positive for ER and PgR, and negative for CD10, CD56, CEA, and p16 (Fig. 3a-e). The WDEA components of both tumors also exhibited PTEN expression and weak phosphorylated Akt expression. The results of the immunohistochemical examination are summarized in Table 2.

**Table 2 Results of the immunohistochemical examination**

|        | NEC  | WDEA |
|--------|------|------|
| AE1/AE3| +    | +    |
| 34β-E12| -    | +    |
| CAM 5.2| ++   | ++   |
| EMA    | +    | +    |
| CEA    | -    | -    |
| ER     | -    | ++   |
| PgR    | -    | ++   |
| CD10   | ++   | -    |
| CD56   | +    | -    |
| Chromogranin | - | - |
| Synaptophysin | + | - |
| S-100  | -    | -    |
| p16    | +    | -    |
| AKT1   | +    | +    |
| AKT1 (phospho S473) | + | + |
| PTEN   | +    | +    |
| β-catenin | - | - |

**NEC and WDEA indicate neuroendocrine carcinoma and well differentiated endometrioid adenocarcinoma, respectively.** The intensity of immunohistochemical reactivity is expressed as ++ representing strong intensity, + representing positive but not strong reactivity and, − representing negative.

Discussion

Because endometrial mixed carcinoma is a recently defined category of WHO tumor classification [1], previous studies reported the mixed carcinoma with NEC component as NEC associated other neoplasm in a series of small cell NECs or large cell NECs. We reviewed the literature and extracted 29 cases (Table 3). The mean age of patients was 61 years (from 30 to 88), and the most common histological combination was NEC and endometrioid adenocarcinoma. The present case is the second youngest and the longest survival case of this carcinoma. Among the extracted cases, 12 died within 3 years and only 5 cases, including our patient, had long-term survival of 3 years or more. These cases were treated with different methods of therapy. One case was treated only with surgery, two other cases underwent chemotherapy in addition to surgery, and the remaining cases were treated with a combination of surgery, radiation and chemotherapy. We could not find a common therapeutic regimen among the cases with long-term survival. Albores-Saavedra et al. reported 5 cases of polypoid small cell NEC including one mixed carcinoma with NEC component and suggested that polypoid endometrial NEC shows favorable prognosis [7]. In agreement with their observation, our case also showed bulky lesions of the endometrium and cervix, however, FIGO stage of the present case was more advanced than that of the previous case (FIGO II versus FIGO IA). Matsumoto et al. reported that the patient was still alive without the disease 4 years after the surgery despite recurrence, but the prognostic factors that contributed to the positive outcome were unknown [9].

The present case survived without tumor recurrence for 6 years after the surgery despite exhibiting FIGO stage II. As described earlier, the prognosis of endometrial mixed carcinoma is correlated with the highest grade component. The histological grading of NEC is an important prognostic factor in non-gynecological sites. Ki-67 labeling index and mitotic rate are currently used for the grading of neuroendocrine tumors (carcinoid, atypical carcinoid, small cell carcinoma, and large cell carcinoma), and these factors are well correlated with the prognosis [17, 18]. However, histological grading by use of the Ki-67 labeling index and mitotic rate for the uterine cervical NEC has not been demonstrated, because the prognostic outcome is poor regardless of the histological grading [19–21]. Although several studies have reported poor prognosis of endometrial NEC [2, 5, 6, 9, 22, 23], the effect of histological grade of NEC on the prognosis was not clarified. The present case showed 5–12 mitotic counts/10HPF and the ratio corresponds to neuroendocrine tumor grade 2 of the digestive system [24]. The relatively low counts of mitotic figures in our case may contribute to favorable prognosis, however, further studies are necessary to establish the significance of histological grade in NEC component in the endometrial mixed carcinoma.

The present case showed strong CD10 expression in the NEC component and also exhibited positive PTEN expression.
expression and weak phosphorylated Akt expression. With regards to molecular correlation between CD10 expression and favorable prognosis, CD10 is associated with cancer through its inhibitory effect on cell migration and proliferation [10]. The molecular mechanism of these effects induced by CD10 is associated with the cleavage and inactivation of fibroblast growth factor 2 (FGF2) [25] or direct binding with PTEN, leading to

Table 3  Clinical and pathological features of endometrial mixed carcinoma with NEC component in the literature and in the present case

| Case | Reference        | Year | Age | Stage | Associated neoplasm                        | Treatment                          | Outcome            |
|------|------------------|------|-----|-------|--------------------------------------------|------------------------------------|--------------------|
| 1    | Tohya et al. [30]| 1986| 64  | IIIb  | Endometrioid adenosquamous carcinoma       | Surgery                            | AWD 3 months       |
| 2    | Tenti et al. [31]| 1989| 70  | Mb    | Endometrioid adenocarcinoma                | Surgery, Chemotherapy, Hormonal therapy | DOD 2 years        |
| 3    | Campo et al. [32]| 1992| 72  | UK    | Poorly differentiated adenocarcinoma       | Radiotherapy                       | DOD 6 months       |
| 4    | Huntsman et al. [2]| 1994| 72  | IIa   | Endometrioid adenocarcinoma                | Surgery, Radiotherapy              | AWD 13 months      |
| 5    | Huntsman et al. [2]| 1994| 55  | IV    | Endometrioid adenocarcinoma                | Radiotherapy, Chemotherapy         | DOD 12 months      |
| 6    | Huntsman et al. [2]| 1994| 54  | Mb    | Atypical complex hyperplasia               | Surgery                            | DOD 12 months      |
| 7    | Huntsman et al. [2]| 1994| 30  | Mb    | Atypical complex hyperplasia               | Surgery                            |                   |
| 8    | Huntsman et al. [2]| 1994| 37  | Mb    | Endometrioid adenocarcinoma                | Surgery                            |                   |
| 9    | Huntsman et al. [2]| 1994| 70  | IIa   | Endometrioid adenocarcinoma                | Surgery, Radiotherapy              | DOD 1 year         |
| 10   | Huntsman et al. [2]| 1994| 62  | IIIa  | Endometrioid adenocarcinoma                | Surgery                            | DOD 2 months       |
| 11   | Huntsman et al. [2]| 1994| 59  | Ic    | Endometrioid adenocarcinoma                | Surgery, Radiotherapy, Chemotherapy | DOD 4 years        |
| 12   | Huntsman et al. [2]| 1994| 58  | Mb    | Endometrioid adenocarcinoma                | Surgery                            | DOD 4 months       |
| 13   | Huntsman et al. [2]| 1994| 53  | IIa   | Endometrioid adenocarcinoma                | Surgery                            | NED 2 months       |
| 14   | van Hoeven et al. [22]| 1995| 59  | I     | Adenocarcinoma                             | Surgery                            | AWD 2 years        |
| 15   | van Hoeven et al. [22]| 1995| 62  | I     | Adenocarcinoma                             | Surgery                            | AWD 1.5 years      |
| 16   | Sekiguchi et al. [33]| 1998| 60  | Ib    | Adenocarcinoma, Squamous cell carcinoma    | Surgery                            | DOD 28 months      |
| 17   | Katahira et al. [6]| 2004| 54  | Ib    | Endometrioid adenocarcinoma, Squamous cell carcinoma | Surgery, Chemotherapy              | NED 28 months      |
| 18   | Shaco-Levy et al. [34]| 2004| 79  | UK    | Papillary serous carcinoma                 | Surgery, Radiotherapy              | DOD 5 months       |
| 19   | Mulvany and Allen [5]| 2007| 80  | Ic    | Endometrioid adenocarcinoma                | Surgery                            | DOD 5 months       |
| 20   | Mulvany and Allen [5]| 2007| 77  | IIb   | Endometrioid adenocarcinoma                | Surgery, Radiotherapy              | DOD 23 months      |
| 21   | Mulvany and Allen [5]| 2007| 79  | IIIa  | Endometrioid adenocarcinoma                | Surgery, Radiotherapy              | AWD 2 months       |
| 22   | Mulvany and Allen [5]| 2007| 88  | IIIc  | Endometrioid adenocarcinoma                | Surgery, Radiotherapy              | AWD 1 month        |
| 23   | Albores-Saavedra et al. [7]| 2008| 66  | Ia    | Endometrioid adenocarcinoma                | Surgery                            | NED 4 years        |
| 24   | Hwang et al. [35]| 2010| 59  | Ic    | Endometrioid adenocarcinoma, Squamous cell carcinoma | Surgery, Radiotherapy, Chemotherapy | NED 15 months      |
| 25   | Sato et al. [8]| 2010| 56  | Mb    | Endometrioid adenocarcinoma                | Surgery, Chemotherapy              | DOD 3 years        |
| 26   | Matsumoto et al. [9]| 2011| 44  | IIIc  | Atypical complex hyperplasia               | Surgery, Radiotherapy, Chemotherapy | NED 4 years        |
| 27   | Koo et al. [36]| 2014| 52  | Ia    | Endometrioid adenocarcinoma, Atypical complex hyperplasia | Surgery, Chemotherapy              | NED 15 months      |
| 28   | Koo et al. [36]| 2014| 63  | Ib    | Endometrioid adenocarcinoma, Atypical complex hyperplasia | Surgery, Chemotherapy              | NED 5 months       |
| 29   | Current report case| 2015| 33  | II    | Endometrioid adenocarcinoma                | Surgery, Chemotherapy              | NED 6 years        |

UK unknown, DOD dead on disease, AWD alive with disease, NED alive without evidence of disease, LFU lost to follow-up
the enhancement of stability and activity, which result in the inhibition of the Akt pathway [26]. These inhibitory effects on cell migration and proliferation allow CD10 to prevent the aggressive behavior of tumor cells [10, 26]. Therefore, we assume that CD10 expression in the NEC component has an anti-cancer effect by retaining the expression of PTEN, which leads to decreased phosphorylated Akt expression. Although the NEC component is usually considered as a poor prognostic factor, the inhibitory effects of CD10 may have contributed to the favorable outcome seen in the present case.

We were unable to identify any other study that examined the correlation between CD10 expression in endometrial NEC and prognosis. As described earlier, CD10 is a favorable prognostic marker in some tumors such as B-lymphoblastic leukemia/lymphoma [27, 28] but unfavorable in others [14]. Intriguingly, the expression patterns of CD10 are correlated with the prognosis of renal clear cell carcinoma. The apical extracellular expression of CD10 shows better prognosis than cytoplasmic or intracellular membrane expression [29]. Because the prognostic value of CD10 may differ depending on the type of tissue from which the tumor arises, further studies are necessary to elucidate the significance of CD10 expression in prognosis.

Conclusions
We reported a case of endometrial mixed carcinoma with NEC component showing favorable prognosis despite being FIGO stage II. Marked CD10 expression in the NEC component was associated with a retained expression of PTEN and a decreased expression of phosphorylated Akt, which may have resulted in anti-cancer effects and contributed to the favorable prognosis.

Consent
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
KU: contributed to the concept, prepared the manuscript, and performed the immunohistochemical examination. FI and YK conducted the immunohistochemical evaluation. IN and MO contributed to the final histopathological diagnosis and approved the manuscript. MI cared for the patient and approved the manuscript. TK conceived the idea and participated in writing of the manuscript. All the authors read and approved the final manuscript.

Acknowledgements
We thank Mr. Zensei Toyoda and Mr. Yoshihide Oshiro (University of the Ryukyus) for their technical assistance.

Author details
1Division of Morphological Pathology, Department of Basic Laboratory Sciences, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. 2Department of Pathology, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, 118-1 Arakawa Haebaru, Okinawa 901-1193, Japan. 3Health Information Management Major, Faculty of International Studies, Meio University, 1220-1 Biemata, Nago, Okinawa 905-8585, Japan. 4Department of Medical Science of Woman and Reproduction, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.

Received: 3 July 2015 Accepted: 12 November 2015
Published online: 01 February 2016

References
1. Zaino R, Matias-Guiu X, Carinelli SG, Mutter GL, Ellenson LH, Peters III WA, et al. Tumors of the uterine corpus. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2014. p. 132.
2. Huntsman DG, Clement PB, Gilks CB, Scully RE. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol. 1994;18:64–75.
3. Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract. Am J Clin Pathol. 2001;115(Suppl):S94–S112.
4. Atenza-Amores M, Gueirini-Rocco E, Soslow RA, Park JI, Weigelt B. Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. Gynecol Oncol. 2014;134:410–8.
5. Mulvany NJ, Allen DG. Combined large cell neuroendocrine and endometroid carcinoma of the endometrium. Int J Gynecol Pathol. 2008;27:49–57.
6. Katahira A, Akahira J, Niikura H, Ito K, Moriya T, Matsuura S, et al. Small cell carcinoma of the endometrium: report of three cases and literature review. Int J Gynecol Cancer. 2004;14:1018–23.
7. Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol. 2008;27:333–9.
8. Sato H, Kanai G, Kajiwara H, Itoh J, Osamura RY. Small-cell carcinoma of the endometrium presenting as Cushing’s syndrome. Endocr J. 2010;57:31–8.
9. Matsumoto H, Takai N, Nasu K, Narahara H. Small cell carcinoma of the endometrium: a report of two cases. J Obstet Gynaecol Res. 2011;37:1739–43.
10. Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29:389–96.
11. Choi WW, Weisbunger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:4904–502.
12. Teraschi M, Kajiya H, Shibata K, Ito, Kizutani S, Kikikawa F. Anti-progressive effect of neutral endopeptidase 24111 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology. 2005;69:52–62.
13. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Hagiya-Miyamoto M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49:489–96.
14. Deschamps L, Handra-Luca A, O’Toole D, Sauvane A, Ruzsniewski P, Belgatti J, et al. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol. 2006;37: 802–8.
15. Velazquez EF, Yancovitz M, Pavlick A, Berman R, Shapiro R, Bogunovic D, et al. Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med. 2007;5:2.
16. Piattelli A, Fioroni M, Iezzi G, Perrotti V, Stellini E, Piattelli M, et al. CD10 expression in stromal cells of oral cavity squamous cell carcinoma: a clinicopathologic correlation. Oral Dis. 2006;12:301–4.
17. La Rosa S, Seisa F, Capella C, Riva C, Leone BE, Kleary C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.
18. Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasm. Endocr Relat Cancer. 2011;18 Suppl 1:51–16.
19. Delage S, Pautier P, Kerbrat P, Castaigne D, Haie-Meder C, Duvillard P, et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol (R Coll Radiol). 2000;12:357–62.

20. Weed Jr JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg. 2003;197:44–51.

21. Walker AN, Mills SE, Taylor PT. Cervical neuroendocrine carcinoma: a clinical and light microscopic study of 14 cases. Int J Gynecol Pathol. 1988;7:64–74.

22. van Hoeven KH, Hudock JA, Woodruff JM, Suhrland MJ. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol. 1995;14:21–9.

23. Ableer YM, Kjonstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer. 1991;68:98–105.

24. Rindi G, Klimstra DS, Arnold R, Koppel G, Bosman FT, Komminoth P, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneilo F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 13–4.

25. Goodman Jr OB, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, et al. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem. 2006;281:33597–605.

26. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005;1751:52–9.

27. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111:5477–85.

28. Dakka N, Bellaoula H, Bouzid N, Kathabi M, Baki Y, Benjouad A. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111:5477–85.

29. Tohya T, Miyazaki K, Katabuchi H, Fujisaki S, Maeyama M. Small cell carcinoma of the endometrium associated with adenosquamous carcinoma: a light and electron microscopic study. Gynecol Oncol. 1986;25:363–71.

30. Tenti P, Carnevali L, Paulli M, Franchi M, Babilioti L. Dedifferentiating endometrial adenocarcinoma. Report of a case. Eur J Gynaecol Oncol. 1989;10:292–4.

31. Campo E, Brunier MN, Merino MJ. Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. Cancer. 1992;69:2283–8.

32. Sekiguchi I, Suzuki M, Sato I, Ohkawa T, Kawanishi H, Tsuchida S. Rare case of small-cell carcinoma arising from the endometrium with paraneoplastic retinopathy. Gynecol Oncol. 1998;71:454–7.

33. Shaco-Levy R, Manor E, Piura B, Ariel I. An unusual composite endometrial tumor combining papillary serous carcinoma and small cell carcinoma. Am J Surg Pathol. 2004;28:1103–6.

34. Hwang JH, Lee JK, Lee NW, Lee KW. Primary small cell carcinoma of the endometrium: report of a case with immunohistochemical studies. J Reprod Med. 2010;55:81–6.

35. Koo YJ, Kim DY, Kim KR, Kim JH, Kim YM, Kim YT, et al. Small cell neuroendocrine carcinoma of the endometrium: a clinicopathologic study of six cases. Taiwan J Obstet Gynecol. 2014;53:355–9.